Modern radiotherapy as part of combined modality treatment in locally advanced non-small cell lung cancer: Present status and future prospects

Oncologist

Volumn 13, Issue 6, 2008, Pages 700-708

  Van Meerbeeck, Jan P ^a   Meersschout, Sabine ^a   De Pauw, Rebecca ^a   Madani, Indira ^a   De Neve, Wilfried ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Chemoradiotherapy; IMRT; Lung cancer; Radiotherapy; Stage III

Indexed keywords

FLUORODEOXYGLUCOSE; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

ADVANCED CANCER; CANCER CONTROL; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG NON SMALL CELL CANCER; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; LUNG NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 45849131811     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2007-0196     Document Type: Review

References (58)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J Clin 2007;57:43-66.
2. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-1717.
3. Chapet O, Kong FM, Quint LE et al. CT-based definition of thoracic lymph node stations: An atlas from the University of Michigan. Int J Radiat Oncol Biol Phys 2005;63:170-178.
4. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J Nucl Med 2007;48(suppl 1):78S-88S.
5. Silvestri GA, Gould MK, Margolis ML et al. Noninvasive staging of nonsmall cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition). Chest 2007;132(3 suppl):178S-201S.
6. Annema JT, Versteegh MI, Veselic M et al. Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging. J Clin Oncol 2005;23:8357-8361.
7. Tournoy KG, Praet MM, Van Maele G et al. Esophageal endoscopic ultrasound with fine-needle aspiration with an on-site cytopathologist: High accuracy for the diagnosis of mediastinal lymphadenopathy. Chest 2005;128:3004-3009.
8. NSCLC Collaborative Group. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995;311:899-909.
9. Aupérin A, Rolland E, Curran WJ et al. NSCLC Collaborative Group. Concomitant radio-chemotherapy (RT-CT) versus sequential RT-CT in locally advanced non-small cell lung cancer (NSCLC): A meta-analysis using individual patient data (IPD) from randomised clinical trials (RCTs). J Thorac Oncol 2007;2:S310.
10. van Meerbeeck JP, Kramer GW, Van Schil PE et al. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:442-450.
11. Albain KS, Swann RS, Rusch V et al. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA (pN2) non-small cell lung cancer: Outcomes update on North American Intergroup 0139. J Clin Oncol 2005;23(16 suppl):624.
12. Johnson DH, Rusch VW, Turrisi AT. Scalpels, beams, drugs, and dreams: Challenges of stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 2007;99:415-418.
13. Robinson LA, Ruckdeschel JC, Wagner H Jr et al. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132(3 suppl):243S-265S.
14. Le Chevalier T, Arriagada R, Tarayre M et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992;84:58.
15. Blackstock AW, Govindan R. Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol 2007;25:4146-4152.
16. Senan S. Staging nodal disease in non-small cell lung cancer: Implications for radiation therapy. J Thorac Oncol 2007;2:585-587.
17. Senan S, Chapet O, Lagerwaard FJ et al. Defining target volumes for nonsmall cell lung carcinoma. Semin Radiat Oncol 2004;14:308-314.
18. Yuan S, Yu J, Sun X et al. Three dimensional conformal involved-field RT for stage III NSCLC. J Clin Oncol 2006;24(18 suppl):375.
19. Senan S, De Ruysscher D, Giraud P et al. Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer. Radiother Oncol 2004;71:139-146.
20. Belani CP, Wang W, Johnson DH et al. Eastern Cooperative Oncology Group. Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): Induction chemotherapy followed by either standard thoracic radiovan therapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer. J Clin Oncol 2005;23:3760-3767.
21. Madani I, De Ruyck K, Goeminne H et al. Predicting risk of radiationinduced lung injury. J Thorac Oncol 2007;2:864-874.
22. Graham MV, Purdy JA, Emami B et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-329.
23. Wei X, Liu HH, Tucker SL et al. Risk factors for acute esophagitis in nonsmall-cell lung cancer patients treated with concurrent chemotherapy and three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:100-107.
24. De Ruysscher D, Wanders S, van Haren E et al. Selective mediastinal node irradiation based on FDG-PET scan data in patients with non-small-cell lung cancer: A prospective clinical study. Int J Radiat Oncol Biol Phys 2005;62:988-994.
25. Cox J, Chang J, Liao Z et al. Acute esophageal reactions from proton beam therapy and concurrent chemotherapy for non-small cell lung cancer (NSCLC): Reduction in incidence and severity despite higher doses. J Thorac Oncol 2007;2:S449.
26. Derycke S, Van Duyse B, De Gersem W et al. Non-coplanar beam intensity modulation allows large dose escalation in stage III lung cancer. Radiother Oncol 1997;45:253-261.
27. Mohan R, Wu Q, Wang X et al. Intensity modulation optimization, lateral transport of radiation, and margins. Med Phys 1996;23:2011-2021.
28. Sharpe MB, Miller BM, Wong JW. Compensation of x-ray beam penumbra in conformal radiotherapy. Med Phys 2000;27:1739-1745.
29. Dirkx ML, Essers M, van Sornsen de Koste JR et al. Beam intensity modulation for penumbra enhancement in the treatment of lung cancer. Int J Radiat Oncol Biol Phys 1999;44:449-454.
30. Ford EC, Mageras GS, Yorke E et al. Respiration-correlated spiral CT: A method of measuring respiratory-induced anatomic motion for radiation treatment planning. Med Phys 2003;30:88-97.
31. Van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol 2004;14:52-64.
32. Bortfeld T, Jiang SB, Rietzel E. Effects of motion on the total dose distribution. Semin Radiat Oncol 2004;14:41-51.
33. Timmerman RD, Park C, Kavanagh BD. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol 2007;2(suppl 3):S101-S112.
34. Wong JW, Sharpe MB, Jaffray DA et al. The use of active breathing control (ABC) to reduce margin for breathing motion. Int J Radiat Oncol Biol Phys 1999;44:911-919.
35. Giraud P, Yorke E, Jiang S et al. Reduction of organ motion effects in IMRT and conformal 3D radiation delivery by using gating and tracking techniques. Cancer Radiother 2006;10:269-282.
36. Mageras GS, Yorke E. Deep inspiration breath hold and respiratory gating strategies for reducing organ motion in radiation treatment. Semin Radiat Oncol 2004;14:65-75.
37. Leith JT, Bliven SF, Lee ES et al. Intrinsic and extrinsic heterogeneity in the responses of parent and clonal human colon carcinoma xenografts to photon irradiation. Cancer Res 1984;44:3757-3762.
38. Vanderstraeten B, Reynaert N, Paelinck L et al. Accuracy of patient dose calculation for lung IMRT: A comparison of Monte Carlo, convolution/ superposition, and pencil beam computations. Med Phys 2006;33:3149-3158.
39. Tanderup K, Olsen DR, Grau C. Dose painting: Art or science? Radiother Oncol 2006;79:245-248.
40. Fowler JF, Tomé WA, Fenwick JD, Mehta MP. A challenge to traditional radiation oncology. Int J Radiat Oncol Biol Phys 2004;60:1241-1256.
41. Fuks Z, Kolesnick R. Engaging the vascular component of the tumor response. Cancer Cell 2005;8:89-91.
42. Timmerman R, McGarry R, Yiannoutsos C et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol 2006;24:4833-4839.
43. Senan S, Haasbeek NJ, Smit EF et al. Stereotactic radiotherapy for centrally located early-stage lung tumors. J Clin Oncol 2007;25:464.
44. Yom SS, Liao Z, Liu HH et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2007;68:94-102.
45. Holloway CL, Robinson D, Murray B et al. Results of a phase I study to dose escalate using intensity modulated radiotherapy guided by combined PET/CT imaging with induction chemotherapy for patients with non-small cell lung cancer. Radiother Oncol 2004;73:285-287.
46. De Neve W, De Wagter C. Lethal pneumonitis in a phase I study of chemotherapy and IMRT for NSCLC: The need to investigate the accuracy of dose computation. Radiother Oncol 2005;75:246-247.
47. Mageras GS. Introduction: Management of target localization uncertainties in external-beam therapy. Semin Radiat Oncol 2005;15:133-135.
48. Hayman JA, Martel MK, Ten Haken RK et al. Dose escalation in non-small-cell lung cancer using three-dimensional conformal radiation therapy: Update of a phase I trial. J Clin Oncol 2001;19:127-136.
49. Fritz P, Kraus HJ, Mḧlnickel W et al. Stereotactic, single-dose irradiation of stage I non-small cell lung cancer and lung metastases. Radiat Oncol 2006;1:30.
50. Hof H, Herfarth KK, Mn̈ter M et al. Stereotactic single-dose radiotherapy of stage I non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 2003;56:335-341.
51. Nagata Y, Takayama K, Matsuo Y et al. Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 2005;63:1427-1431.
52. Onimaru R, Shirato H, Shimizu S et al. Tolerance of organs at risk in smallvolume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys 2003;56:126-135.
53. Onishi H, Kuriyama K, Komiyama T et al. Clinical outcomes of stereotactic radiotherapy for stage I non-small cell lung cancer using a novel irradiation technique: Patient self-controlled breath-hold and beam switching using a combination of linear accelerator and CT scanner. Lung Cancer 2004;45:45-55.
54. Timmerman R, Papiez L, McGarry R et al. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 2003;124:1946-1955.
55. Uematsu M, Shioda A, Suda A et al. Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: A 5-year experience. Int J Radiat Oncol Biol Phys 2001;51:666-670.
56. Wulf J, Baier K, Mueller G et al. Dose-response in stereotactic irradiation of lung tumors. Radiother Oncol 2005;77:83-87.
57. Zimmermann FB, Geinitz H, Schill S et al. Stereotactic hypofractionated radiation therapy for stage I non-small cell lung cancer. Lung Cancer 2005;48:107-114.
58. Giraud P, Kantor G, Loiseau H et al. Target definition in the thorax and central nervous system. Semin Radiat Oncol 2005;15:146-156.